Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.
作者： Michael S Gordon , Molly L Young , Martin S Tallman , Larry D Cripe , John M Bennett
DOI: 10.1016/S0145-2126(00)00043-6
关键词:
摘要: 2-Chlorodeoxyadenosine (2-CdA) is a purine analog which has anti-leukemic activity in phase II trials pediatric acute myeloid leukemia (AML) patients. An adult I trial suggested possible similar although neurotoxicity at higher doses was seen. We conducted of 2-CdA patients with relapsed or refractory AML. administered by continuous intravenous infusion dose 17 mg/m(2) per day x5 days. Patients not achieving aplasia 21 were eligible for second course therapy. Fifteen (nine and six AML) enrolled including seven men eight women median age 60 years ECOG PS 1. There five deaths on study due to infections (two), AML hepatic failure (one). The well tolerated without severe nausea, vomiting stomatitis (all
elsevier.com
sci-hub.se 参考文章(20)
James C Biggs, Mary M Horowitz, Robert Peter Gale, Robert C Ash, Kerry Atkinson, Werner Helbig, Niels Jacobsen, Gordon L Phillips, Alfred A Rimm, Olle Ringden, Ciril Rozman, Kathleen A Sobocinski, Judith A Veum, Mortimer M Bortin, Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy Blood. ,vol. 80, pp. 1090- 1093 ,(1992) , 10.1182/BLOOD.V80.4.1090.1090
H Kawasaki, CJ Carrera, LD Piro, A Saven, TJ Kipps, DA Carson, Relationship of deoxycytidine kinase and cytoplasmic 5'-nucleotidase to the chemotherapeutic efficacy of 2-chlorodeoxyadenosine Blood. ,vol. 81, pp. 597- 601 ,(1993) , 10.1182/BLOOD.V81.3.597.597
Hagop M Kantarjian, Miloslav Beran, Amy Ellis, Leonard Zwelling, Susan O'Brien, Lorraine Cazenave, Charles Koller, Mary Beth Rios, William Plunkett, Michael J Keating, Elihu H Estey, Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia Blood. ,vol. 81, pp. 1146- 1151 ,(1993) , 10.1182/BLOOD.V81.5.1146.BLOODJOURNAL8151146
Rainer Koob, Raymond L. Blakley, Johannes Griffig, Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Research. ,vol. 49, pp. 6923- 6928 ,(1989)
R. W. Brockman, W. B. Parker, L. M. Rose, Chi-Hsiung Chang, A. T. Shortnacy, L. Lee Bennett, S. C. Shaddix, E. L. White, J. A. Montgomery, J. A. Secrist, Effects of 2-Chloro-9-(2-deoxy-2-fluoro-β-d-arabinofuranosyl)adenine on K562 Cellular Metabolism and the Inhibition of Human Ribonucleotide Reductase and DNA Polymerases by Its 5′-Triphosphate Cancer Research. ,vol. 51, pp. 2386- 2394 ,(1991)
Steven A. Rosenberg, Vincent T. DeVita, Samuel Hellman, Cancer : Principles and Practice of Oncology ,(1982)
L Vahdat, ET Wong, MJ Wile, M Rosenblum, KM Foley, RP Jr Warrell, Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia Blood. ,vol. 84, pp. 3429- 3434 ,(1994) , 10.1182/BLOOD.V84.10.3429.3429
Richard A. Ashmun, Thomas L. Avery, Min-Chi Huang, Raymond L. Blakley, Michael Kuehl, Effects of cytotoxicity of 2-chloro-2'-deoxyadenosine and 2-bromo-2'-deoxyadenosine on cell growth, clonogenicity, DNA synthesis, and cell cycle kinetics. Cancer Research. ,vol. 46, pp. 2362- 2368 ,(1986)
R Ohno, K Okada, T Masaoka, A Kuramoto, T Arima, Y Yoshida, H Ariyoshi, M Ichimaru, Y Sakai, M Oguro, AN EARLY PHASE II STUDY OF CPT-11 : A NEW DERIVATIVE OF CAMPTOTHECIN, FOR THE TREATMENT OF LEUKEMIA AND LYMPHOMA Journal of Clinical Oncology. ,vol. 8, pp. 1907- 1912 ,(1990) , 10.1200/JCO.1990.8.11.1907
B D Cheson, P A Cassileth, D R Head, C A Schiffer, J M Bennett, C D Bloomfield, R Brunning, R P Gale, M R Grever, M J Keating, Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. Journal of Clinical Oncology. ,vol. 8, pp. 813- 819 ,(1990) , 10.1200/JCO.1990.8.5.813